Clinical Trials Sponsored by Imugen

Total 1534 results

Amgen

Completed

A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma
Amgen

Completed

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects

Inflammatory Disease

New Zealand
Amgen

Terminated

A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Amgen

Withdrawn

Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease

Solid Tumor | Metastatic Bone Disease
Amgen

Completed

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject

Chronic Pain
Amgen

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain

Osteoarthritis
Amgen

Completed

Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose

Healthy Volunteer

United States
Amgen

Terminated

20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)

Schizophrenia

United States, France, United Kingdom, Malaysia, Poland, Czech Republic
Amgen

Terminated

Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

Systemic Lupus Erythematosus | Cutaneous Lupus | Lupus | Discoid Lupus

United States
Amgen

Completed

Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis

Systemic Lupus Erythematosus | Nephritis

United States, Hong Kong, France, Malaysia, Mexico
Amgen

Completed

Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease

Anemia | Chronic Kidney Disease

France, Italy, United Kingdom, Belgium, Hungary, Spain, Israel, Portugal, Bulgaria, Serbia, Poland, Romania, Greece, Australia, Denmark, Russian Federation, Slovakia, Germany, Latvia, Estonia, Slovenia, Czech Republic, Mexico
Amgen

Completed

Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Colon Cancer

United States
Amgen

Terminated

Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis

Anemia

United States
Amgen

Completed

Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer (SPECTRUM)

Recurrent and/or Metastatic Head and Neck Cancer
Amgen

Completed

Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study

Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Colon Cancer | Oncology
Amgen

Completed

Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer

Breast Cancer | Metastases | Bone Metastases in Subjects With Advanced Breast Cancer
Amgen

Completed

Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer

Colorectal Cancer
Amgen

Completed

A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab

Osteoporosis | Postmenopausal Osteoporosis | Low Bone Mineral Density | Low Bone Mass
Amgen

Completed

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis

Rheumatoid Arthritis

United States, United Kingdom
Amgen

Completed

Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma
Amgen

Completed

Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer

Locally Recurrent and Metastatic Breast Cancer
Amgen

Completed

Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)

Rheumatoid Arthritis
Amgen

Completed

AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies

Cancer
Amgen

Completed

Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma

Carcinoma | Colorectal Cancer
Amgen

Completed

Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels

End Stage Renal Disease
Amgen

Completed

A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood

Breast Cancer | Ovarian Cancer | Lung Cancer
Amgen

Completed

Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)

End Stage Renal Disease
Amgen

Completed

Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy

Neutropenia
Amgen

Completed

Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy

Stomatitis
Amgen

Completed

12-month Study of AMG 073 in Renal Osteodystrophy

Renal Osteodystrophy
Amgen

Completed

A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism

Hyperparathyroidism, Primary
Amgen

Completed

A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

Hyperparathyroidism | Parathyroid Neoplasms
Amgen

Completed

Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa

Anemia | Non-Myeloid Malignancies
Amgen

Terminated

Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects

Diabetes Mellitus

United States
Amgen

Terminated

Single Ascending Dose Trial in Patients With Type 2 Diabetes

Diabetes Mellitus

United States
Amgen

Completed

A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates

Postmenopausal Osteoporosis
Amgen

Completed

A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

Myelodysplastic Syndromes | Thrombocytopenia
Amgen

Completed

Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis

Chronic Kidney Disease
Amgen

Completed

A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors

Histologically or Cytologically Documented Solid Tumors
Amgen

Completed

Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors

Solid Tumors
Amgen

Completed

Study To Evaluate the Status of Subjects That Discontinued Participation in a Qualifying Amgen Sponsored AMG 073 Study Due to Kidney Transplantation

Kidney Transplantation
Amgen

Completed

Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer

Colorectal Cancer
Amgen

Completed

Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology

Idiopathic Thrombocytopenic Purpura
Amgen

Completed

A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis
Amgen

Completed

STAAR-2 Clinical Study

Chronic Kidney Disease | Chronic Renal Insufficiency | Kidney Disease | Pre-dialysis | Pre-ESRD
Amgen

Completed

EPO Deep Tank in Dialysis Subjects

Chronic Kidney Disease
Amgen

Completed

Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

Anemia | Non-Myeloid Malignancies
Amgen

Completed

Phase 2 Study of Darbepoetin Alfa Extended Dosing

Pre-Dialysis
Amgen

Terminated

A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy

Cancer | Anemia
Amgen

Completed

Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy

Non-Small Cell Lung Cancer

3

Subscribe